VistaGen Therapeutics's total assets for Q4 2025 were $84.34M, a decrease of -8.63% from the previous quarter. VTGN total liabilities were $13.95M for the fiscal quarter, a 24.73% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.